Limits...
Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients

View Article: PubMed Central - PubMed

ABSTRACT

Background: The clinical course of gastric lymphoma is heterogeneous and clinical symptoms and some factors have been related to prognosis.

Objective: The present study aims to identify prognostic factors in gastric diffuse B-cell non-Hodgkin lymphoma diagnosed and treated in different countries.

Methods: A consecutive series of gastric diffuse B-cell non-Hodgkin lymphoma patients diagnosed and treated in Brazil, Portugal and Italy, between February 2008 and December 2014 was evaluated.

Results: Of 104 patients, 57 were female and the median age was 69 years (range: 28–88). The distribution of the age-adjusted international prognostic index was 12/95 (13%) high risk, 20/95 (21%) high-intermediate risk and 63/95 (66%) low/low-intermediate risk. Symptoms included abdominal pain (63/74), weight loss (57/73), dysphagia (37/72) and nausea/vomiting (37/72). Bulky disease was found in 24% of the cases, anemia in 33 of 76 patients and bleeding in 22 of 72 patients. The median follow-up time was 25 months (range: 1–77 months), with 1- and 5-year survival rates of 79% and 76%, respectively. The multivariate Cox Regression identified the age-adjusted international prognostic index as a predictor of death (hazard risk: 3.62; 95% confidence interval: 2.21–5.93; p-value <0.0001).

Conclusions: This series identified the age-adjusted international prognostic index as predictive of mortality in patients treated with conventional immunochemotherapy.

No MeSH data available.


The 5-year overall survival.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4997895&req=5

fig0005: The 5-year overall survival.

Mentions: The five-year overall survival was 76% [95% confidence interval (CI): 68–84%] (Figure 1) and 46/71 (64%) achieved complete response. Over a median follow-up of 25 months (range: 1–77 months), the 1- and 5-year survival rates were 79% and 76%, respectively. There were 22 deaths. Only four stage I–II cases (18%) had progressive disease compared to 18 (82%) patients with advanced disease hence, patients with localized lymphoma (I–II) had a significantly higher 5-year survival probability (91%) compared with those with advanced-stage (64%; p-value = 0.003). The 5-year survival of high-risk aaIPI patients was significantly inferior to low-risk patients (91% versus 44%; p-value <0.0001: Table 2).


Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients
The 5-year overall survival.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4997895&req=5

fig0005: The 5-year overall survival.
Mentions: The five-year overall survival was 76% [95% confidence interval (CI): 68–84%] (Figure 1) and 46/71 (64%) achieved complete response. Over a median follow-up of 25 months (range: 1–77 months), the 1- and 5-year survival rates were 79% and 76%, respectively. There were 22 deaths. Only four stage I–II cases (18%) had progressive disease compared to 18 (82%) patients with advanced disease hence, patients with localized lymphoma (I–II) had a significantly higher 5-year survival probability (91%) compared with those with advanced-stage (64%; p-value = 0.003). The 5-year survival of high-risk aaIPI patients was significantly inferior to low-risk patients (91% versus 44%; p-value <0.0001: Table 2).

View Article: PubMed Central - PubMed

ABSTRACT

Background: The clinical course of gastric lymphoma is heterogeneous and clinical symptoms and some factors have been related to prognosis.

Objective: The present study aims to identify prognostic factors in gastric diffuse B-cell non-Hodgkin lymphoma diagnosed and treated in different countries.

Methods: A consecutive series of gastric diffuse B-cell non-Hodgkin lymphoma patients diagnosed and treated in Brazil, Portugal and Italy, between February 2008 and December 2014 was evaluated.

Results: Of 104 patients, 57 were female and the median age was 69 years (range: 28&ndash;88). The distribution of the age-adjusted international prognostic index was 12/95 (13%) high risk, 20/95 (21%) high-intermediate risk and 63/95 (66%) low/low-intermediate risk. Symptoms included abdominal pain (63/74), weight loss (57/73), dysphagia (37/72) and nausea/vomiting (37/72). Bulky disease was found in 24% of the cases, anemia in 33 of 76 patients and bleeding in 22 of 72 patients. The median follow-up time was 25 months (range: 1&ndash;77 months), with 1- and 5-year survival rates of 79% and 76%, respectively. The multivariate Cox Regression identified the age-adjusted international prognostic index as a predictor of death (hazard risk: 3.62; 95% confidence interval: 2.21&ndash;5.93; p-value &lt;0.0001).

Conclusions: This series identified the age-adjusted international prognostic index as predictive of mortality in patients treated with conventional immunochemotherapy.

No MeSH data available.